MktsMarkets

Design Therapeutics, Inc.
NASDAQ: DSGNKey statistics
DSGN News
Stories mentioning DSGN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | ||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Operating Expenses | ||||||||
| Research & Development | 14,379 | 13,425 | 14,589 | 15,738 | 15,377 | 12,157 | 11,876 | 10,516 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 19,706 | 18,169 | 19,311 | 21,569 | 20,418 | 16,694 | 16,246 | 15,043 |
| Operating Income (Loss) | (19,706) | (18,169) | (19,311) | (21,569) | (20,418) | (16,694) | (16,246) | (15,043) |
| Interest Income | 2,070 | 2,172 | 2,314 | 2,486 | 2,703 | 3,043 | 3,207 | 3,250 |
| Interest Expense | ||||||||
| Other Expense | 3,207 | 3,250 | ||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (17,636) | (15,997) | (16,997) | (19,083) | (17,715) | (13,651) | (13,039) | (11,793) |
| Earnings Per Share (Basic) | (0.29) | (0.28) | (0.30) | (0.34) | (0.31) | (0.24) | (0.23) | (0.21) |
| Earnings Per Share (Diluted) | (0.29) | (0.28) | (0.30) | (0.34) | (0.31) | (0.24) | (0.23) | (0.21) |
| Weighted Average Shares Outstanding (Basic) | 61,434 | 57,330 | 56,951 | 56,859 | 56,758 | 56,587 | 56,621 | 56,556 |
| Weighted Average Shares Outstanding (Diluted) | 61,434 | 57,330 | 56,951 | 56,859 | 56,758 | 56,587 | 56,621 | 56,556 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About DSGN
Design Therapeutics, Inc. (NASDAQ: DSGN) is a stock listed on the Nasdaq Stock Market under the ticker symbol DSGN. It last traded at $10.22 (Nov 16, 2026, 10:18 AM ET), down 2.4% on the day. That gives Design Therapeutics a market capitalisation of $670.5M.
Over the past 52 weeks DSGN has traded between $6.81 and $17.25.
Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $17.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | $0 | -$17.6M |
| Dec 31, 2025 | — | -$16.0M |
| Sep 30, 2025 | — | -$17.0M |
| Jun 30, 2025 | — | -$19.1M |
From Design Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…